Get the Stockscreener App
34.04
0.90%
-0.31
Pre-market:
34.00
-0.04
-0.12%
Vera Therapeutics Inc stock is traded at $34.04, with a volume of 448.61K.
It is down -0.90% in the last 24 hours and down -15.47% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$34.35
Open:
$34.3
24h Volume:
448.61K
Relative Volume:
0.38
Market Cap:
$2.44B
Revenue:
-
Net Income/Loss:
$-299.62M
P/E Ratio:
-7.2986
EPS:
-4.6639
Net Cash Flow:
$-241.73M
1W Performance:
-8.79%
1M Performance:
-15.47%
6M Performance:
+19.61%
1Y Performance:
+73.41%
1-Day Range:
$33.91
$34.88
1-Week Range:
$32.81
$37.44
52-Week Range:
$18.76
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
34.04 | 2.47B | 0 | -299.62M | -241.73M | -4.6639 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
VERA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
VERA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vera Therapeutics, Inc.Class A Common Stock (NQ: VERA - FinancialContent
UBS Group AG Boosts Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Why (VERA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment) - Stock Titan
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $91 - Moomoo
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com - Investing.com Canada
Vera Therapeutics president and CEO sells $679,747 in stock - Investing.com UK
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $110 - Moomoo
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
Vera Therapeutics (VERA) Receives a Buy from Guggenheim - The Globe and Mail
TradingKey - TradingKey
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
The Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-Up - Yahoo! Finance Canada
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Does Vera’s Widening Quarterly Net Loss Reframe the Bull Case for Vera Therapeutics (VERA)? - Sahm
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(C)(4) - TradingView
Ten new hires get Vera stock awards tied to 60,375 shares - Stock Titan
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
Vera Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Vera Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Vera Therapeutics (VERA) ramps spending as atacicept nears key FDA decision - Stock Titan
LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vera Therapeutics, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Kidney disease drug gets July 7 FDA date as Vera readies launch - Stock Titan
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - marketscreener.com
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
Vera Therapeutics faces earnings test ahead of FDA verdict - Investing.com UK
Vera Therapeutics faces earnings test ahead of FDA verdict By Investing.com - Investing.com South Africa
Understanding Momentum Shifts in (VERA) - Stock Traders Daily
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference - The Manila Times
Vera Therapeutics to present May 13 at Bank of America health conference - Stock Titan
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA - MarketBeat
Vera Therapeutics (VERA) to Release Earnings on Tuesday - MarketBeat
HC Wainwright & Co. Maintains Vera Therapeutics (VERA) Buy Recommendation - MSN
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):